MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Relmada Therapeutics Income Statement 2011-2025 | RLMD
Annual Income Statement Relmada Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
162 M | 71.4 M | 360 M | 510 M | 53.8 M | 15.7 M | 9.78 M | 22.3 M | 72.1 M | 37.4 M | - | - | - |
Shares |
30.1 M | 29.6 M | 17.6 M | 15.6 M | 6.31 M | 3.14 M | 3.02 M | 2.9 M | 2.49 M | 620 K | - | - | - |
Historical Prices |
5.37 | 2.41 | 20.5 | 33.3 | 48.8 | 5.32 | 2.8 | 3.24 | 6 | 54.8 | - | - | - |
Net Income |
-98.8 M | -157 M | -126 M | -59.5 M | -17.3 M | -8.96 M | -6.29 M | -2.97 M | -20.8 M | -21.3 M | -45 K | -12.1 K | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | 5.13 K | 7.94 K | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | 4.04 K | 5.8 K | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 1.09 K | 2.14 K | - |
Operating Income |
-104 M | -161 M | -126 M | -60.8 M | -15.1 M | -6.92 M | -7.22 M | -16.2 M | -17.1 M | - | -6.77 M | -3.16 M | - |
Interest Expense |
5.15 M | 2.66 M | 1.2 M | 1.4 M | 104 K | -1.34 M | 932 K | 13.2 M | 4.92 K | - | 220 K | 27.7 K | - |
EBITDA |
-104 M | -161 M | -126 M | -60.8 M | -12.7 M | -6.91 M | -7.13 M | -16.2 M | -17.1 M | -29.7 M | -44.8 K | -11.3 K | - |
Operating Expenses |
104 M | 161 M | 126 M | 60.8 M | 12.7 M | 6.92 M | 7.22 M | 16.2 M | 17.1 M | 13 M | 46.1 K | 13.8 K | - |
General and Administrative Expenses |
48.9 M | 47.9 M | 35.1 M | 24.9 M | 5.7 M | 3.97 M | 5.93 M | 10 M | 9.23 M | 12.1 M | 45.1 K | 9.09 K | - |
All numbers in USD currency
Quarterly Income Statement Relmada Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
33.2 M | 33.2 M | 30.2 M | 30.2 M | 30.2 M | 30.1 M | 30.1 M | 30.1 M | 30.1 M | 30.1 M | 30.1 M | 30.1 M | 29.9 M | 29.4 M | 27.7 M | 17.5 M | 17.1 M | 16.6 M | 16.3 M | 16 M | 15.3 M | 14.7 M | 14.5 M | 9.76 M | 8.25 M | 9.76 M | 25.6 M | 3.14 M | 19.1 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12 M | 12 M | 12 M | 12 M | 12 M | 11.4 M | 10.8 M | 11.4 M | 10.8 M | 10.2 M | 8.15 M | 8.06 M | 49.8 M | 28.5 M | 2.45 M | 23.5 M | 24 M | 23.5 M | 13.9 M | 14.1 M | 14 M | - | - | - | - |
Net Income |
-10.1 M | -9.87 M | - | -21.7 M | -17.8 M | -21.8 M | - | -22 M | -25.3 M | -26.3 M | - | -39.4 M | -39.9 M | -39.7 M | - | -42.6 M | -26.6 M | -22.2 M | - | -16.9 M | -11.1 M | -10.7 M | - | -3.67 M | -4.12 M | -3.67 M | -7.13 M | -3.38 M | -7.13 M | -3.38 M | -1.43 M | -982 K | -1.43 M | -982 K | -1.03 M | -1.64 M | -1.03 M | -1.64 M | -2.46 M | 4.66 M | -2.46 M | 4.66 M | 5.46 M | -29.8 M | 5.46 M | -29.8 M | -5.17 M | -1.57 M | -13.2 K | -14.4 K | -9.02 K | -3.42 K | -942 | - | - | -90 | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | -552 K | 9.48 K | -15 K | - | -513 K | -176 K | -52.8 K | - | -245 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 682 | 1.85 K | - | 634 | 14.9 K | 2.15 K | 6.43 K | 400 | 6.03 K | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 685 | 1.69 K | - | 322 | 11.5 K | 1.85 K | 4.8 K | 292 | 4.51 K | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3 | 164 | - | 312 | 3.4 K | 299 | 1.62 K | 108 | 1.52 K | - | - | - | - |
Operating Income |
-10.3 M | -10.2 M | - | -23 M | -18.8 M | -23 M | - | -22.7 M | -26 M | -28.2 M | - | -38.7 M | -45.5 M | -38.3 M | - | -42.7 M | -26.5 M | -22.4 M | - | -17.2 M | -12.8 M | -9.97 M | - | -3.71 M | -4.14 M | -3.71 M | -3.48 M | -2.41 M | -5.89 M | -2.41 M | -1.46 M | -981 K | -1.46 M | -981 K | -1.54 M | -1.62 M | -1.54 M | -1.62 M | -5.72 M | -4.63 M | -5.72 M | -4.63 M | -4.38 M | -3.72 M | -4.38 M | -3.72 M | -5.06 M | -482 K | -19.5 K | -14.4 K | -9.02 K | -3.42 K | -2.48 K | -503 | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | 1.32 M | 1.36 M | 1.21 M | - | 828 K | 387 K | 330 K | - | 298 K | 323 K | 420 K | - | 363 K | 404 K | 408 K | - | 37.9 K | - | 15.9 K | -140 K | -650 K | -790 K | -652 K | 29.2 K | -830 | 28.4 K | 301 K | 506 K | -24 K | 506 K | -24 K | 1.17 K | 1.64 K | 2.81 K | 125 | 1.1 K | 3.27 K | 1.1 K | 3.27 K | 112 K | 67 K | - | 29.4 K | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | - | - | - | - | - | -38.7 M | -45.5 M | -38.3 M | - | -42.7 M | -26.5 M | -22.4 M | - | -17.2 M | -12.8 M | -9.97 M | - | -3.71 M | -4.13 M | -3.71 M | -3.48 M | -2.41 M | -5.89 M | -2.41 M | -1.46 M | -980 K | -1.46 M | -980 K | -1.54 M | -1.6 M | -1.49 M | -1.6 M | -5.72 M | -4.63 M | -5.72 M | -4.63 M | -4.38 M | -3.72 M | -4.38 M | -3.72 M | -5.06 M | -482 K | -19.5 K | -14.4 K | -9.02 K | -3.42 K | -2.48 K | -503 | - | - | - | - |
Operating Expenses |
10.3 M | 10.2 M | - | 23 M | 18.8 M | 23 M | - | 22.7 M | 26 M | 28.2 M | - | 38.7 M | 45.5 M | 38.3 M | - | 42.7 M | 26.5 M | 22.4 M | - | 17.2 M | 12.8 M | 9.97 M | - | 3.71 M | 4.14 M | 3.71 M | 3.48 M | 2.41 M | 5.89 M | 2.41 M | 1.46 M | 981 K | 1.46 M | 981 K | 1.54 M | 1.62 M | 1.54 M | 1.62 M | 5.72 M | 4.63 M | 5.72 M | 4.63 M | 4.38 M | 3.72 M | -4.38 M | -3.72 M | -5.06 M | -482 K | 19.8 K | 14.5 K | 9.32 K | 5.05 K | 2.59 K | 2.02 K | - | - | - | - |
General and Administrative Expenses |
6.29 M | 7.4 M | - | 11.9 M | 8.1 M | 9.68 M | - | 12.2 M | 12.3 M | 12.3 M | - | 8.21 M | 14.6 M | 13.3 M | - | 8.66 M | 9.13 M | 8.38 M | - | 5.95 M | 7.43 M | 5.47 M | - | 1.82 M | 1.07 M | 1.82 M | 2.22 M | 990 K | 3.21 M | 990 K | 1.31 M | 815 K | 1.31 M | 815 K | 1.28 M | 1.25 M | 1.28 M | 1.25 M | 3.6 M | 1.76 M | 3.6 M | 1.76 M | 2.29 M | 3 M | -2.29 M | -3 M | -789 K | -207 K | 19.8 K | 14.5 K | 9.01 K | 992 | 2.59 K | 878 | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Relmada Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
$ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
$ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
$ 3.07 | -6.25 % | $ 1.6 B | Canada |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
$ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
$ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
$ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
$ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
$ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
$ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
$ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
$ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
$ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
$ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.8 | -6.19 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
$ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
$ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
$ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
$ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
$ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
$ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
$ 1.99 | -9.95 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
$ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
$ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
$ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
$ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
$ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
$ 11.68 | 0.29 % | $ 14.2 B | USA |